bioRxivMicrobiologyPreprint
An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants
W. Du, D. L. Hurdiss, D. Drabek, A. Z. Mykytyn, F. Kaiser, M. Gonzalez-Hernandez, D. Munoz-Santos, M. M. Lamers, R. van Haperen, W. Li, I. Drulyte, C. Wang, I. Sola, F. Armando, G. Beythien, M. Ciurkiewicz, W. Baumgartner, K. Guilfoyle, T. Smits, J. van der Lee, F. J. M. van Kuppeveld, G. van Amerongen, B. L. Haagmans, L. Enjuanes, A. D. Osterhaus, , B. J. Bosch
Abstract
The ongoing evolution of SARS-CoV-2 has resulted in the emergence of Omicron, which displays striking immune escape potential. Many of its mutations localize to the spike protein ACE2 receptor-binding domain, annulling the neutralizing activity of most therapeutic monoclonal antibodies. Here we describe a receptor-blocking human monoclonal antibody, 87G7, that retains ultrapotent neutralization against SARS-CoV-2 variants including the Alpha, Beta, Gamma, Delta and Omicron (BA.1/BA.2) Variants-of-Concern (VOCs). Structural analysis reveals that 87G7 targets a patch of hydrophobic residues in the ACE2-binding site that are highly conserved in SARS-CoV-2 variants, explaining its broad neutralization capacity. 87G7 protects mice and/or hamsters against challenge with all current SARS-CoV-2 VOCs. Our findings may aid the development of sustainable antibody-based strategies against COVID-19 that are more resilient to SARS-CoV-2 antigenic diversity. One sentence summaryA human monoclonal antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants
- organism: human
- assay: proteomics
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
E. Cameroni, C. Saliba, … P·bioRxiv·Dec 12, 2021
- Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody to antigenically distinct omicron SARS-CoV-2 subvariants
S. Changrob, P. J. Halfmann, … P. C. Wilson·bioRxiv·Oct 31, 2022
- Humanized antibody potently neutralizes all SARS-CoV-2 variants by a novel mechanism
- Intranasal delivery of a broadly neutralizing single domain antibody targeting ACE2 protects against SARS-CoV-2 infection
Simon Blachier, Ignacio Fernández, … Anne Brelot·bioRxiv·Oct 11, 2024
- Clinical grade ACE2 effectively inhibits SARS-CoV-2 Omicron infections
Vanessa Monteil, Stéphanie Devignot, … Alì Mirazimi·bioRxiv·Dec 25, 2021
- Potent neutralization by a receptor binding domain monoclonal antibody with broad specificity for SARS-CoV-2 JN.1 and other variants
Michael S. Piepenbrink, Ahmed Magdy Khalil, … James J. Kobie·npj VirusesPeer-reviewed·Nov 14, 2024